The National Comprehensive Cancer Network (NCCN) Clinical Practical Guidelines in Oncology (www.nccn.org/guidelines) recommends this drug for the treatment of advanced HCC in patients with moderate liver dysfunction (i.e. CP B7). The gene discussed is CP; the disease is Decreased liver function.